Comparative In-Vitro Quality Assessment of Commercially Available Isosorbide Dinitrate 10 mg Tablet Formulations
DOI:
https://doi.org/10.47957/ijpda.v14i3.758Keywords:
Isosorbide dinitrate, angina pectoris, nitric oxide, vasodilation, cardiovascular therapy, drug deliveryAbstract
Isosorbide dinitrate (ISDN) is a well-known organic nitrate that is frequently used to treat heart failure and angina pectoris because of its potent vasodilatory activity. The pharmacological profile, mechanisms of action, therapeutic uses, and new developments in formulation techniques are the main topics of this review article's thorough assessment of ISDN. The medication's effects on nitric oxide pathway modulation, myocardial oxygen supply-demand balance, and preload and afterload reduction in cardiovascular diseases are highlighted. The article also discusses safety concerns and limitations such as tolerance development, and clinical evidence for its effectiveness. In order to improve therapeutic results, novel therapeutic strategies including combination regimens and medication administration are also covered. Overall, this review highlights the ongoing importance of ISDN in cardiovascular medication and suggests possible avenues for further study and therapeutic application.
Downloads
References
Rinaldi R, Kunadian V, Crea F, Montone RA. Management of angina pectoris. Trends in Cardiovascular Medicine. 2025. doi:10.1016/j.tcm.2025.03.001
Anonymous. APHA (American Public Health Association) conference report, 1964. A special section. Public health reports. 1965.
Avram A, Chioncel V, Guberna S, Cuciureanu I, Brezeanu RC, Andrei CL, et al. Myocardial bridging - an unusual cause of Wellens syndrome: A case report. Medicine (United States). 2020;99(41). doi:10.1097/MD.0000000000022491
Zahr FE, Mulukutla SR, Marroquin OC. A contemporary overview of the pathophysiology of angina pectoris. Reviews in Cardiovascular Medicine. 2013. doi:10.3909/ricm13S1S0003
Totsuka Sutto SE, Rodríguez Roldan YI, Cardona Muñoz EG, Garcia Cobian TA, Pascoe Gonzalez S, Martínez Rizo A, et al. Efficacy and safety of the combination of isosorbide dinitrate spray and chitosan gel for the treatment of diabetic foot ulcers: A double-blind, randomized, clinical trial. Diab Vasc Dis Res. 2018;15(4). doi:10.1177/1479164118769528
Winchester DE, Pepine CJ. Angina treatments and prevention of cardiac events: An appraisal of the evidence. European Heart Journal, Supplement. 2015. doi:10.1093/eurheartj/suv054
Tarkin JM, Kaski JC. Pharmacological treatment of chronic stable angina pectoris. Clinical Medicine, Journal of the Royal College of Physicians of London. 2013. doi:10.7861/clinmedicine.13-1-63
Cao HY, Wu H Di, Song ZK, Tang ML, Yang S, Liu Y, et al. Higher than recommend dosage of sublingual isosorbide dinitrate for treating angina pectoris: A case report and review of the literature. Pan African Medical Journal. 2021;39. doi:10.11604/pamj.2021.39.28.22180
Schaumann W. Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate. International Journal of Clinical Pharmacology Therapy and Toxicology. 1989.
Yager N, Konduru S, Torosoff M. Nitrates as a Marker of Multiple Co-morbidities and Increased Mortality in Patients Undergoing Percutaneous Coronary Intervention (PCI). Cureus. 2022. doi:10.7759/cureus.23520
Fanaroff AC, Kaltenbach LA, Peterson ED, Hess CN, Cohen DJ, Fonarow GC, et al. Management of persistent angina after myocardial infarction treated with percutaneous coronary intervention: Insights from the TRANSLATE-ACS study. J Am Heart Assoc. 2017;6(10). doi:10.1161/JAHA.117.007007
Grimmsmann T, Chenot JF, Angelow A. Effects of expiring reimbursability of pentaerythrityl tetranitrate (PETN, pentalong®) on anti-anginal therapy: An observational study. Pharmacoepidemiol Drug Saf. 2015;24(8). doi:10.1002/pds.3802
Schmid JP, Schroeder V. Nicorandil - Review of pharmacological properties and clinical applications. HeartDrug. 2005. doi:10.1159/000089603
Parang P, Singh B, Arora R. Metabolic modulators for chronic cardiac ischemia. Journal of Cardiovascular Pharmacology and Therapeutics. 2005. doi:10.1177/107424840501000402
Frishman WH, Pepine CJ, Weiss RJ, Baiker WM. Addition of zatebradine, a direct sinus node inhibitor, provides no greater exercise tolerance benefit in patients with angina taking extended-release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J Am Coll Cardiol. 1995;26(2). doi:10.1016/0735-1097(95)80000-7
Borges JMDM, de Carvalho FO, Gomes IA, Rosa MB, Sousa ACS. Antiplatelet agents in perioperative noncardiac surgeries: To maintain or to suspend? Therapeutics and Clinical Risk Management. 2018. doi:10.2147/TCRM.S172591
Shastry S, Prudhivi R, S V, Lugun A, Mounika TS, Christopher S. PATTERN OF PHARMACOTHERAPY AND ASSESSMENT OF DRUG RELATED PROBLEMS IN ISCHEMIC HEART DISEASE PATIENTS. International Research Journal Of Pharmacy. 2019;10(3). doi:10.7897/2230-8407.100392
McCALLUM A, BUCHTER J, ALBRECHT R. Comparison and correlation of the Strong Cobb and the Monsanto tablet hardness testers. J Am Pharm Assoc Am Pharm Assoc (Baltim). 1955;44(2). doi:10.1002/jps.3030440208
Osei-Yeboah F, Sun CC. Validation and applications of an expedited tablet friability method. Int J Pharm. 2015;484(1–2). doi:10.1016/j.ijpharm.2015.02.061
Sirasitthichoke C, Patel S, Reuter KG, Hermans A, Bredael G, Armenante PM. Influence of basket mesh size on the hydrodynamics in the USP rotating basket dissolution testing Apparatus 1. Int J Pharm. 2021;607. doi:10.1016/j.ijpharm.2021.120976
Fu M, Al-gousous J, Blechar JA, Langguth P. Enteric hard capsules for targeting the small intestine: Positive correlation between in vitro disintegration and dissolution times. Pharmaceutics. 2020;12(2). doi:10.3390/pharmaceutics12020123
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
